Dose Insider / Glossary / GLP-1 and anesthesia

GLP-1 medicines and anesthesiaAspiration risk and what guidance says

Updated November 20, 2026 · 3 min read · ZEPBOUND label; multisociety guidance 2024; BMJ 2024 cohort

GLP-1 medicines slow the emptying of the stomach, so food can still be there at the time of surgery or deep sedation even after the usual fasting. That raises a concern about pulmonary aspiration, when stomach contents enter the lungs. The labels report rare cases of it and ask patients to tell their care team about any planned procedure.

9.8Procedure stopped, GLP-1 medicine, before upper endoscopy
Before upper endoscopyRisk per 1,000 people, BMJ cohortPULMONARY ASPIRATIONGLP-1 medicine4.2SGLT-2 inhibitor4.3PROCEDURE STOPPEDGLP-1 medicine9.8SGLT-2 inhibitor4.9Before upper endoscopyRisk per 1,000 people, BMJ cohortPULMONARY ASPIRATIONGLP-1 medicine4.2SGLT-2 inhibitor4.3PROCEDURE STOPPEDGLP-1 medicine9.8SGLT-2 inhibitor4.9

No more aspiration, but twice as many stopped procedures.

On this page

A 2024 guidance from five medical societies allows most people to keep taking the medicine, with extra care for those at higher risk.1,2

What the labels say

The Zepbound label notes that tirzepatide delays gastric emptying and that there have been rare post-approval reports of pulmonary aspiration in people on GLP-1 medicines who had elective surgery or procedures under general anesthesia or deep sedation. Some had food left in the stomach despite following the fasting instructions. The label says the available data are not enough to recommend how to lower the risk, and it asks patients to tell their providers about planned surgeries or procedures.1

The 2024 multisociety guidance

Five groups wrote the guidance together. They were the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery and the American Society of Anesthesiologists. Two more joined: the International Society of Perioperative Care of Patients with Obesity and the Society of American Gastrointestinal and Endoscopic Surgeons.2 Its main points:

Kindel et al., 2024.2

Who is at higher risk

The guidance lists the features that raise the risk of a slow stomach around a procedure:2

It asks for that check early enough before surgery to allow changes in the plan.2

What studies found

A 2024 study in the BMJ compared 24,817 adults on GLP-1 medicines with 18,537 on SGLT-2 inhibitors before upper endoscopy; both groups averaged about 60 years of age, and 64% were women. Pulmonary aspiration occurred in 4.15 and 4.26 per 1,000 people, no difference. But the procedure had to be stopped twice as often in the GLP-1 group, 9.79 against 4.91 per 1,000, a risk ratio of 1.99, which fits food left in the stomach.3

In practice

The practical steps follow from the labels and the guidance: tell the surgical team the medicine, the dose and the date of the last dose, mention any nausea, vomiting or bloating, and follow their instructions about diet and timing. Whether to pause the medicine, and for how long, is their decision, made with the surgeon and the prescriber. Our page on how long Zepbound stays in your system shows how the level falls after a dose.

Sources

  1. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 5 and 17. accessdata.fda.gov
  2. Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc 2025;39:180-183. Representing the AGA, ASMBS, ASA, ISPCOP and SAGES. doi:10.1007/s00464-024-11263-2
  3. Alkabbani W, Suissa K, Gu KD, et al. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. BMJ 2024;387:e080340. doi:10.1136/bmj-2024-080340

Related analyses

Log your last dose and any stomach symptoms, so you can tell the surgical team exactly.

Open Dose Insider